Myomo Aims for $100 Million Revenue Goal by 2028

Myomo, Inc. (NYSE:MYO) is listed as one of the 10 Best Small Cap Robotics Stocks to Buy Now. The company recently held an Investor and Analyst Day to discuss its business model and long-term goals. Myomo aims to reach $100 million in annual revenue by 2028, with a portion coming from international customers and its O&P channel. The company specializes in wearable robotics for patients with neurological disorders and upper limb paralysis.

During the Investor Day, Myomo highlighted its Q1 FY2025 performance and emphasized the untapped market of prospective MyoPro patients. The company is focused on lead generation to overcome challenges faced earlier in the quarter. Myomo management believes there is still room for growth in advertising saturation.

While Myomo presents investment potential, some AI stocks may offer higher upside and lower downside risk. For those interested in undervalued AI stocks with benefits from current economic trends, consider exploring other investment options. The company’s focus on wearable robotics for patients with neurological disorders remains a key aspect of its business model.

Read more at Yahoo Finance: Myomo Reveals its $100 Revenue Goal During Investor Day